Castle Biosciences COO Oelschlager sells $138,642 in shares

Chief Operating Officer Kristen M. Oelschlager of Castle Biosciences Inc. (CSTL) sold 4,152 shares of the company's common stock on September 1, 2026, for a total of $138,642. The sales were made at prices between $33.015 and $34.02 per share, following the exercise of stock options for an equal number of shares. The company's stock is currently trading at $32.65, up 44% over the past year despite recent market weakness.

Oelschlager executed these transactions under a Rule 10b5-1 trading plan she established on March 17, 2026. Prior to the sales, she had purchased 4,152 shares through stock options at $3.38 per share, totaling $14,033. These shares were fully vested and were part of the trading plan. After the sales, she directly holds 13,356 shares, with an additional 72,649 shares indirectly held through The Fritz Shorter Trust, where she and her spouse are trustees and beneficiaries.

She also retains 12,458 stock options, which are fully vested and expire on March 12, 2029. Castle Biosciences has a market cap of $996 million, although the company remains unprofitable. The company recently reported second-quarter results that surpassed Wall Street expectations, posting an adjusted loss of 7 cents per share and revenue of $103.5 million.

Castle Biosciences has raised its full-year sales guidance, signaling confidence in future performance. BTIG recently raised its price target for CSTL to $44 from $40, maintaining a Buy rating, citing strong revenue growth driven by the TissueCypher franchise, which experienced a 63% increase in volumes year-over-year and 28% increase quarter-over-quarter.